Loading...

We've got a brand new version of Simply Wall St! Try it out

Ortho Regenerative Technologies

CNSX:ORTH
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORTH
CNSX
CA$8M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The last earnings update was 75 days ago. More info.


Add to Portfolio Compare Print
  • Ortho Regenerative Technologies has significant price volatility in the past 3 months.
ORTH Share Price and Events
7 Day Returns
0%
CNSX:ORTH
3.1%
CA Biotechs
1.2%
CA Market
1 Year Returns
-22.5%
CNSX:ORTH
-72.8%
CA Biotechs
-0.2%
CA Market
ORTH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ortho Regenerative Technologies (ORTH) 0% 34.8% -11.4% -22.5% - -
CA Biotechs 3.1% 10.9% -2.4% -72.8% -20.6% 26.7%
CA Market 1.2% 4.2% 1.5% -0.2% 8.4% 1.8%
1 Year Return vs Industry and Market
  • ORTH outperformed the Biotechs industry which returned -72.8% over the past year.
  • ORTH underperformed the Market in Canada which returned -0.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Ortho Regenerative Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Ortho Regenerative Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Ortho Regenerative Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ortho Regenerative Technologies. This is due to cash flow or dividend data being unavailable. The share price is CA$0.31.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ortho Regenerative Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ortho Regenerative Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ORTH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in CAD CA$-0.10
CNSX:ORTH Share Price ** CNSX (2019-09-13) in CAD CA$0.31
North America Biotechs Industry PE Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 18.78x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 14.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ortho Regenerative Technologies.

CNSX:ORTH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ORTH Share Price ÷ EPS (both in CAD)

= 0.31 ÷ -0.10

-3.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ortho Regenerative Technologies is loss making, we can't compare its value to the North America Biotechs industry average.
  • Ortho Regenerative Technologies is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Ortho Regenerative Technologies's expected growth come at a high price?
Raw Data
CNSX:ORTH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 0.72x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ortho Regenerative Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ortho Regenerative Technologies's assets?
Raw Data
CNSX:ORTH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in CAD CA$-0.05
CNSX:ORTH Share Price * CNSX (2019-09-13) in CAD CA$0.31
Canada Biotechs Industry PB Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 4.13x
Canada Market PB Ratio Median Figure of 2,452 Publicly-Listed Companies 1.44x
CNSX:ORTH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ORTH Share Price ÷ Book Value per Share (both in CAD)

= 0.31 ÷ -0.05

-6.53x

* Primary Listing of Ortho Regenerative Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ortho Regenerative Technologies has negative assets, we can't compare the value of its assets to the CA Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Ortho Regenerative Technologies's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Ortho Regenerative Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ortho Regenerative Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ortho Regenerative Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ortho Regenerative Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.9%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ortho Regenerative Technologies expected to grow at an attractive rate?
  • Unable to compare Ortho Regenerative Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ortho Regenerative Technologies's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Ortho Regenerative Technologies's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ORTH Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.9%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 46.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ORTH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ORTH Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-04-30 -1 -3
2019-01-31 -1 -2
2018-10-31 -2 -3
2018-07-31 -2 -2
2018-04-30 -2 -2
2018-01-31 -2 -2
2017-10-31 -2 -1
2017-07-31 -2 -1
2017-04-30 -1 -2
2017-01-31 -2 -2
2016-10-31 -1 -2
2016-07-31 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ortho Regenerative Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Ortho Regenerative Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ORTH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ortho Regenerative Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORTH Past Financials Data
Date (Data in CAD Millions) EPS *
2019-04-30 -0.10
2019-01-31 -0.10
2018-10-31 -0.12
2018-07-31 -0.12
2018-04-30 -0.12
2018-01-31 -0.12
2017-10-31 -0.08
2017-07-31 -0.09
2017-04-30 -0.12
2017-01-31 -0.12
2016-10-31 -0.18
2016-07-31 -0.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ortho Regenerative Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Ortho Regenerative Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Ortho Regenerative Technologies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ortho Regenerative Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ortho Regenerative Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ortho Regenerative Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ortho Regenerative Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ortho Regenerative Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ortho Regenerative Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ortho Regenerative Technologies's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ortho Regenerative Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ortho Regenerative Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ORTH Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 -2.54 1.18 1.24
2019-01-31 -2.40 1.22 1.08
2018-10-31 -2.72 1.31 0.87
2018-07-31 -2.34 1.30 0.72
2018-04-30 -2.22 1.28 0.70
2018-01-31 -2.02 1.14 0.65
2017-10-31 -1.26 0.95 0.46
2017-07-31 -1.33 0.83 0.43
2017-04-30 -1.65 0.81 0.69
2017-01-31 -1.66 0.86 0.70
2016-10-31 -2.09 1.05 0.71
2016-07-31 -1.78 0.96 0.53
2016-04-30 -1.16 0.69 0.21
2016-01-31 -0.93 0.52 0.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ortho Regenerative Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Ortho Regenerative Technologies has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ortho Regenerative Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Ortho Regenerative Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ortho Regenerative Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ortho Regenerative Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ortho Regenerative Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ortho Regenerative Technologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Ortho Regenerative Technologies's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Ortho Regenerative Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Ortho Regenerative Technologies has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ortho Regenerative Technologies Company Filings, last reported 4 months ago.

CNSX:ORTH Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 -1.18 1.07 0.03
2019-01-31 -0.59 1.16 0.52
2018-10-31 0.13 0.82 0.36
2018-07-31 0.85 0.79 0.79
2018-04-30 -0.25 1.15 0.06
2018-01-31 0.15 1.12 0.45
2017-10-31 0.58 1.08 1.03
2017-07-31 -0.12 0.78 0.42
2017-04-30 0.56 0.53 0.34
2017-01-31 -1.27 0.88 0.01
2016-10-31 -0.12 0.55 0.02
2016-07-31 -0.31 0.53 0.02
2016-04-30 0.20 0.26 0.00
2016-01-31 0.35 0.24 0.65
  • Ortho Regenerative Technologies has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Ortho Regenerative Technologies's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ortho Regenerative Technologies has less than a year of cash runway based on current free cash flow.
  • Ortho Regenerative Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.7% each year.
X
Financial health checks
We assess Ortho Regenerative Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ortho Regenerative Technologies has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ortho Regenerative Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ortho Regenerative Technologies dividends.
If you bought CA$2,000 of Ortho Regenerative Technologies shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ortho Regenerative Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ortho Regenerative Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ORTH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 58 Stocks 2.1%
Canada Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ortho Regenerative Technologies has not reported any payouts.
  • Unable to verify if Ortho Regenerative Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ortho Regenerative Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ortho Regenerative Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ortho Regenerative Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ortho Regenerative Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ortho Regenerative Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ortho Regenerative Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Claude LeDuc
AGE 63
TENURE AS CEO 0.3 years
CEO Bio

Mr. Claude LeDuc has been the Chief Executive Officer and President at Ortho Regenerative Technologies Inc. since June 17, 2019. He has been Director at Ortho Regenerative Technologies Inc. since June 19, 2019. Mr. LeDu served as President and Chief Executive Officer of BioSyntech Inc. from March 1, 2004 to December 31, 2008. Mr. LeDuc has full marketing and management responsibility for supporting and managing the BioOrthopaedics distribution partners in all global assigned regions, as well as providing franchise support to the worldwide country managers. During his 5-year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho-RTi's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew. He served as Director of International Markets at Genzyme Biosurgery since December 2000. Mr. LeDuc joined the Genzyme International Group in Cambridge, Ma., following his highly successful position as National Director for Canada and his nine year career at Biomatrix Inc., a Biomaterial Medical applications company, where he was responsible with various marketing, sales and business development roles in Canada and Europe. Mr. LeDuc then progressed to the Biotechnology sector in 1991 with Serono Laboratories as a regional marketing and sales manager and then to Biomatrix, Inc. Mr. LeDuc started his health industry career 17 years ago with Syntex Laboratories, a multinational pharmaceutical company, winning a National Performance Award in sales within his first two years. Mr. LeDuc served as a Director of BioSyntech Inc. from 2002 to December 31, 2008.

CEO Compensation
  • Insufficient data for Claude to compare compensation growth.
  • Insufficient data for Claude to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Ortho Regenerative Technologies management team in years:

1
Average Tenure
58.5
Average Age
  • The average tenure for the Ortho Regenerative Technologies management team is less than 2 years, this suggests a new team.
Management Team

Luc Mainville

TITLE
Senior VP & CFO
COMPENSATION
CA$62K
AGE
55
TENURE
1 yrs

Steve Saviuk

TITLE
Executive Chairman
AGE
60

Claude LeDuc

TITLE
President
AGE
63
TENURE
0.3 yrs

Michael Buschmann

TITLE
Chief Scientific Officer & Director
AGE
57
TENURE
4.6 yrs

Frederic Dumais

TITLE
Director of Communications & Investor Relations

Guy Allard

TITLE
VP of Legal Affairs & Corporate Secretary

Benedek Simo

TITLE
Controller
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Ortho Regenerative Technologies board of directors in years:

2
Average Tenure
59.5
Average Age
  • The average tenure for the Ortho Regenerative Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Saviuk

TITLE
Executive Chairman
AGE
60
TENURE
0.5 yrs

Claude LeDuc

TITLE
President
AGE
63
TENURE
0.3 yrs

Michael Buschmann

TITLE
Chief Scientific Officer & Director
AGE
57
TENURE
4.6 yrs

Tom E. Wright

TITLE
Director
AGE
66
TENURE
2 yrs

Jack Farr

TITLE
Member of Scientific Advisory Board

Scott Rodeo

TITLE
Member of Scientific Advisory Board

Martyn Snow

TITLE
Member of Scientific Advisory Board

Caroline Hoemann

TITLE
Director
AGE
59
TENURE
4.4 yrs

Brent Henry Norton

TITLE
Director
COMPENSATION
CA$270K
AGE
58
TENURE
3.2 yrs

Jacques Toueg

TITLE
Member of Scientific Advisory Board
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Ortho Regenerative Technologies individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
04. Sep 19 Buy Luc Mainville Individual 03. Sep 19 03. Sep 19 7,000 CA$0.29 CA$2,000
03. Sep 19 Buy Guy-Paul Allard Individual 03. Sep 19 03. Sep 19 5,000 CA$0.29 CA$1,425
30. Aug 19 Buy Guy-Paul Allard Individual 30. Aug 19 30. Aug 19 14,000 CA$0.25 CA$3,530
19. Aug 19 Buy Luc Mainville Individual 15. Aug 19 15. Aug 19 10,000 CA$0.22 CA$2,200
14. Aug 19 Buy Luc Mainville Individual 13. Aug 19 13. Aug 19 50,000 CA$0.24 CA$12,000
25. Jun 19 Buy Luc Mainville Individual 19. Jun 19 19. Jun 19 25,000 CA$0.31 CA$7,698
X
Management checks
We assess Ortho Regenerative Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ortho Regenerative Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in researching and developing novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a freeze-dried formulation for rotator cuff repair; and Ortho-M, a biopolymer for bilateral meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.

Details
Name: Ortho Regenerative Technologies Inc.
ORTH
Exchange: CNSX
Founded: 2015
CA$7,673,251
24,752,424
Website: http://www.orthorti.com
Address: Ortho Regenerative Technologies Inc.
16667 Hymus Boulevard,
Kirkland,
Quebec, H9H 4R9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ORTH Class A Common Shares Canadian National Stock Exchange CA CAD 10. Oct 2017
Number of employees
Current staff
Staff numbers
0
Ortho Regenerative Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/15 01:35
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/07/02
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/01/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.